Advertisement

Topics

Catalent, hindered by Softgel weakness, sees stronger growth ahead

12:00 EDT 9 May 2019 | BioPharmaDive

Revenues from January to March fell 2% year over year, as the CDMO works through an ibuprofen supply shortage and an accounting change.

Original Article: Catalent, hindered by Softgel weakness, sees stronger growth ahead

NEXT ARTICLE

More From BioPortfolio on "Catalent, hindered by Softgel weakness, sees stronger growth ahead"

Advertisement
Quick Search
Advertisement
Advertisement